Table 3.
Cause of treatment discontinuation (incidence rate >2%)
| Eligible patients (n = 1,775), n (%) |
||
|---|---|---|
| HAIC (n = 429) | sorafenib (n = 1,346) | |
| Any adverse event | 111 (25.9) | 399 (29.6) |
| Catheter-related adverse events | 27 (6.7) | 0 |
| Liver failure | 20 (4.7) | 77 (5.7) |
| General disorders | 3 (0.7) | 49 (3.6) |
| Rash | 0 | 30 (2.2) |
| Catheter occlusion | 10 (2.3) | 0 |
| Hand-foot-skin syndrome | 0 | 30 (2.2) |
| Anorexia | 1 (0.2) | 28 (2.1) |
| Renal failure | 9 (2.1) | 9 (0.7) |
| Abdominal pain | 9 (2.1) | 2 (0.1) |